- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03195764
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
November 17, 2022 updated by: Taivex Therapeutics Corporation
A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors
T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines.
In addition, oral administration of T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human cancers.
In this study, safety, tolerability and PK of T-1101 (Tosylate) will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2 will be determined.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung City 404327, Taiwan
- China Medical University Hospital
-
Tainan, Taiwan, 701
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 110
- Taipei Medical University Hospital
-
Taipei, Taiwan, 115
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Tumor eligibility:
- Histologically confirmed advanced malignancies refractory to standard active treatment.
- Solid tumors that have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy.
- Able, in the investigator's opinion, to have a life expectancy of more than 3 months.
- Female or male, 20 years of age or older.
- ECOG performance status 0 or 1.
- Resolution of all acute toxic effects of prior therapy or surgical procedures to no more than grade 1 (except alopecia).
Adequate organ function as defined by the following criteria:
- Serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or ALT ≤ 5 x ULN if liver tumor is present.
- Total serum bilirubin ≤1.5 x ULN
- WBC ≥ 4000/µL with an absolute neutrophil count (ANC) ≥1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL
- CCr ≥ 50 mL/min
- Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Exclusion Criteria:
- Major surgery (as defined by investigator) within 4 weeks of starting treatment.
- Extensive radiation therapy or systemic cytotoxic chemotherapy within 4 weeks before starting study treatment or target therapy within 2 weeks of starting study treatment.
- Current treatment on clinical trial or within 4 weeks of completion of clinical trial for another investigation drug.
- Documented or suspicious brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.
- Any of the following occurs within 6 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.
- Ongoing cardiac dysrhythmias of NCI CTCAE grade 2, or atrial fibrillation of any grade.
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
- Known human immunodeficiency virus infection.
- Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to the use of highly effective contraception during the period of therapy. Highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1 percent per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, or a vasectomized partner. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.
- Patients with active infection should be excluded.
- Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T-1101 (Tosylate)
|
T-1101 (Tosylate) powder in bottle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of T-1101 (Tosylate) in Participants with Advanced Cancers Refractory to Standard Therapy
Time Frame: The first 21-day cycle
|
MTD is highest dose level in which 6 patients have been treated with at most 1 experiencing dose limiting toxicity (DLT). When following toxicity events occur within the first 21-day cycle, these toxicity will be defined as DLT.
The above toxicities will be graded according to the NCI CTCAE v4.03. |
The first 21-day cycle
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Tumor Response of T-1101 (Tosylate) in Participants with Advanced Cancers
Time Frame: Up to 2 years
|
Categorization of response based on RECIST 1.1.
|
Up to 2 years
|
Pharmacokinetics: Peak maximum plasma concentration (Cmax) and minimum plasma concentration (Cmin) of T-1101 (Tosylate) and its metabolites
Time Frame: Selected time points during first 21-day cycle
|
Selected time points during first 21-day cycle
|
|
Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) to the time of the last measurable concentration and to infinity of T-1101 (Tosylate) and its metabolites
Time Frame: Selected time points during first 21-day cycle
|
Area under the plasma concentration versus time curve to the time of the last measurable concentration (AUC0-last) of T-1101 (Tosylate) and its metabolites will be estimated using non-compartmental analysis.
If data permit, area under the plasma concentration versus time curve to infinity (AUC0-∞) will be also estimated.
|
Selected time points during first 21-day cycle
|
Pharmacokinetics: Time to maximum plasma concentration (Tmax) and terminal half-life (T½) of T-1101 (Tosylate) and its metabolites
Time Frame: Selected time points during first 21-day cycle
|
Time to maximum plasma concentration (Tmax) of T-1101 (Tosylate) and its metabolites will be estimated using non-compartmental analysis.
If data permit, terminal elimination half-life (T½ ) will be also estimated.
|
Selected time points during first 21-day cycle
|
Pharmacokinetics: Oral plasma clearance (CL/F) of T-1101 (Tosylate) and its metabolites
Time Frame: Selected time points during first 21-day cycle
|
Selected time points during first 21-day cycle
|
|
Pharmacokinetics: Apparent volume of distribution (Vd/F) of T-1101 (Tosylate) and its metabolites
Time Frame: Selected time points during first 21-day cycle
|
Selected time points during first 21-day cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2017
Primary Completion (Actual)
October 1, 2019
Study Completion (Actual)
October 23, 2019
Study Registration Dates
First Submitted
May 8, 2017
First Submitted That Met QC Criteria
June 19, 2017
First Posted (Actual)
June 22, 2017
Study Record Updates
Last Update Posted (Actual)
November 18, 2022
Last Update Submitted That Met QC Criteria
November 17, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAI-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Refractory Solid Tumors
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
-
Taivex Therapeutics CorporationActive, not recruitingAdvanced Refractory Solid TumorsTaiwan
-
Taivex Therapeutics CorporationCompletedAdvanced Refractory Solid TumorsTaiwan
-
Sunshine Lake Pharma Co., Ltd.CompletedAdvanced Refractory Solid TumorsChina
-
National OncoVentureChong Kun Dang PharmaceuticalUnknownAdvanced Refractory Solid TumorsKorea, Republic of
-
Piramal Enterprises LimitedSuspendedAdvanced Refractory Solid TumorsUnited States, India
-
Piramal Enterprises LimitedSuspendedAdvanced Refractory Solid TumorsUnited States, India
-
Second Affiliated Hospital of Soochow UniversityRecruitingAdvanced Refractory Solid TumorsChina
-
CStone PharmaceuticalsBayerCompletedAdvanced Refractory Solid TumorsAustralia
-
Shanghai Pudong HospitalUTC Therapeutics Inc.WithdrawnMesothelin-positive Advanced Refractory Solid TumorsChina
Clinical Trials on T-1101 (Tosylate)
-
Taivex Therapeutics CorporationActive, not recruitingAdvanced Refractory Solid TumorsTaiwan
-
Taivex Therapeutics CorporationCompletedAdvanced Refractory Solid TumorsTaiwan
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
Chimeric TherapeuticsRecruitingGlioblastoma Multiforme of BrainUnited States
-
Daiichi Sankyo Co., Ltd.Active, not recruitingAdult T-cell Leukemia/LymphomaJapan
-
New York State Psychiatric InstituteIntra-Cellular Therapies, Inc.Terminated
-
The Lymphoma Academic Research OrganisationDaiichi SankyoActive, not recruitingStudy of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaLymphoma, B-CellFrance, Belgium
-
Cleave Therapeutics, Inc.CompletedMyelodysplastic Syndromes | Acute Myeloid Leukemia, in RelapseUnited States, Australia
-
Daiichi Sankyo, Inc.Not yet recruitingAdvanced Solid Tumor
-
Jiangsu HengRui Medicine Co., Ltd.Completed